AOP spins off majority stake in cancer vaccine biotech; Ambrx strikes China collaboration deal;

@FierceBiotech: Analysis: Big Pharma R&D demonstrates a woeful lack of innovation. News | Follow @FierceBiotech

 @JohnCFierce: AOP spins off its 80% stake in Activartis (cancer vaccines) after Elan shareholders reject takeover bid. Release | Follow @JohnCFierce

@RyanMFierce: In $247M Transition deal, Eli Lilly is reeling in a diabetes drug candidate that it had spun off (sort of): Yesterday's item | Follow @RyanMFierce

> Soon after Elan's ($ELN) shareholders nixed a series of deals, including the acquisition of Vienna-based AOP Orphan Pharmaceuticals, the biotech announced that it is spinning off its 80% ownership in Activartis--a cancer vaccine developer--to a group of private investors. Release

> Ambrx and China's Zhejiang Medicine Co. will collaborate on the development and commercialization of ARX788, Ambrx's most advanced antibody drug conjugate targeting HER2-positive breast cancer. Release

Pharma News

@FiercePharma: Valeant to sell $2B worth of stock to finance Bausch + Lomb buyout, plus issue $7.5B in debt. More | Follow @FiercePharma

@EricPFierce: India's Roselabs sees lots of upside in prefilled syringes for the Indian market. Story | Follow @EricPFierce

@CarlyHFierce: Bristol-Myers makes another emerging markets move with Simcere partnership in China. Yesterday's story | Follow @CarlyHFierce

> Who wins after SCOTUS pay-for-delay decision? Lawyers. More

> Want a raise, pharma reps? Get into biotech sales instead. Story

Medical Device News

@FierceMedDev: Exact raising $63.7M on rocky road to FDA approval. News | Follow @FierceMedDev

@DamianFierce: Medtronic's Infuse no better than graft procedure but more dangerous, according to independent reviews. More | Follow @DamianFierce

@MichaelGFierce: Check out our new FierceBiotech LinkedIn page... and sign up to join the discussion! LinkedIn group page | Follow @MichaelGFierce

> Boston Scientific targets FDA with brain-stim trial. Story

> Endologix endures FDA deadly warning over recall. Item

> Globus owes $16M in J&J patent suit. Report

Biotech Research News

 @EmilyMFierce: Have you joined the @FierceBiotech LinkedIn group yet? Connect with biotech colleagues and join the discussion: Join now | Follow @EmilyMFierce

> Breast cancer cell growth thwarted by osteoporosis drug in preclinical studies. Report

> New genetic mutations found in families with early-onset Alzheimer's. Item

> Inovio says H7N9 bird flu vaccine effective in mice. Story

> Report: Genomics industry contributed $1 trillion to U.S. economy in last 25 years. More

Pharma Manufacturing News

> French plant part of proposed GSK, Aspen deal. Item

> Roselabs taps growth of prefilled syringe in India. Report

> City forecloses on Indiana insulin plant it helped fund. Article

> Eisai adding packaging facility to U.K. plant. More

And Finally… Investigators say that a low-fat, low-carb diet can reduce the level of beta-amyloid peptides, perhaps reducing the risk of Alzheimer's. Researchers emphasized, though, that they have no firm idea yet if this kind of diet would have a significant impact on the risk of developing the memory-robbing disease that now afflicts millions. Story

Suggested Articles

Novavax delayed the start of a large phase 3 trial for its COVID-19 vaccine in the U.S. and Mexico, thanks to delays in scaling up manufacturing.

The decision to dump IL33r antagonist GSK3772847 follows lackluster clinical data on rival candidates against the same target.  

The deal is worth $50 million upfront but could balloon in value to more than $2 billion if all the milestones are hit.